

## MEDIAN nominates Kapil Dhingra to its board

14 November 2012 | News | By BioSpectrum Bureau

### MEDIAN nominates Kapil Dhingra to its board



**Bangalore:** MEDIAN Technologies, a leading medical imaging software solutions developer, and a service provider for image interpretation and management in oncology clinical trials, from France, announced that its board of directors, chaired by Mr Fredrik Brag, CEO, proposed to appoint Dr Kapil Dhingra as a new director for a period of three years. This decision was made at the board's latest meeting and will be put on the agenda of the next shareholders' meeting.

"Dr Kapil Dhingra will bring us his unique strategic expertise, vision and experience of the global biopharma industry," said Mr Fredrik Brag, chairman and CEO, MEDIAN. "Kapil has a vast experience in bringing innovations to the drug development process in oncology. His knowledge and support will contribute to further enhance MEDIAN growth strategy, in particular as regards to the advanced imaging services that we bring to top tiers Pharmas and Biotechs. We are very proud to have him joining our Board."

"Accurate and consistent evaluation of tumors is crucial to the management of patients with cancer and in clinical trials of new drugs and represents a major unmet technology need in oncology today," said Dr Kapil Dhingra. "The solutions provided by the MEDIAN platform can greatly enhance interpretation and management of images. The ability to obtain high quality and accurate lesion assessment in near-real-time can significantly enhance the efficiency of clinical trials of new drugs."

Dr Dhingra founded KAPital Consulting in 2008 to help biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial promise of advances in oncology. From 1999-to-2008, he served in positions of increasing responsibility at Roche including vice president, head, oncology disease biology leadership team, and head, oncology clinical development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly. From 1989-to-1996, he was a faculty member at the University of Texas' MD Anderson cancer center, where he led a successful laboratory as well as clinical research program.

Throughout his industry career, Dr Dhingra held an active faculty appointment at Indiana University's school of medicine from 1997-99, and more recently, at Memorial Sloan Kettering Cancer Center in New York from 2000-08. Dr Dhingra holds an MBBS degree from the All India Institute of Medical Sciences (AIIMS), and has performed postgraduate work at the AIIMS, the Lincoln Medical and Mental Health Center (New York Medical College), Bronx, and Emory University School of Medicine,

Atlanta, US. He is board-certified in internal medicine and medical oncology.